Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 11/20 | 0.43 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MME | P08473 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6465938 | 1.00 | AGTR1 (0.43) | AGTR1LTB4R2ABCB11GP6MEN1 | |
| SCHEMBL5949171 | 0.92 | AGTR1 (0.53) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL5949176 | 0.92 | AGTR1 (0.53) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL3473866 | 0.92 | AGTR1 (0.50) | AGTR1LTB4R2ABCB11GP6MEN1 | |
| SCHEMBL3473870 | 0.92 | AGTR1 (0.50) | AGTR1LTB4R2ABCB11GP6MEN1 | |
| SCHEMBL6442187 | 0.91 | AGTR1 (0.50) | AGTR1LTB4R2ABCB11GP6MEN1 | |
| SCHEMBL27620717 | 0.91 | AGTR1 (0.50) | AGTR1LTB4R2ABCB11GP6MEN1 | |
| SCHEMBL2950 | 0.84 | AGTR1 (0.61) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL2691 | 0.84 | AGTR1 (0.61) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL14193717 | 0.84 | AGTR1 (0.61) | AGTR1LTB4R2ABCB11GP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050197372-A1 | Use of valsartan or its metabolite to inhibit platelet aggregation | MALININ ALEX (US) | 2005-09-08 | — | — | US | disclosed |
| EP-1505965-A1 | USE OF VALSARTAN OT ITS METABOLITE TO INHIBIT PLATELET AGGREGATION | Novartis AG (CH) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003094915-A1 | USE OF VALSARTAN OT ITS METABOLITE TO INHIBIT PLATELET AGGREGATION | NOVARTIS AG (CH) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197372-A1 | Use of valsartan or its metabolite to inhibit platelet aggregation | PTAFR, PDGFRA, ACE | AGTR1 14/4885LTB4R2 311/4885ABCB11 2341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.